NCT00496808View on ClinicalTrials.gov

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Ductal Carcinoma In Situ
Interventions
DRUG

Herceptin (Trastuzumab)

8 mg/kg IV Over 90 Minutes

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00496808 - Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast | Biotech Hunter | Biotech Hunter